Why the study?
Differentiating Takotsubo cardiomyopathy from ischemic or dilated cardiomyopathy is challenging in clinical practice, especially in subacute settings or atypical presentations.
Do serum biomarkers (sST2, GDF-15, suPAR, H-FABP) differentiate Takotsubo cardiomyopathy from ischemic and dilated cardiomyopathies?
Do serum biomarkers (sST2, GDF-15, suPAR, H-FABP) differentiate Takotsubo cardiomyopathy from ischemic and dilated cardiomyopathies?
Serum biomarkers, particularly sST-2, may facilitate the differential diagnosis of Takotsubo cardiomyopathy from ischemic and dilated cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
sST2 shows promise for differentiating TTC from ICMP/DCMP; leaves open whether it refines diagnosis or warrants prospective validation before clinical use.
Topf et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: